These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 28087740)
1. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. Zhang M; Osisami M; Dai J; Keller JM; Escara-Wilke J; Mizokami A; Keller ET Mol Cancer Res; 2017 Apr; 15(4):457-466. PubMed ID: 28087740 [TBL] [Abstract][Full Text] [Related]
2. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598 [TBL] [Abstract][Full Text] [Related]
3. The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy. Seed RI; Taurozzi AJ; Wilcock DJ; Nappo G; Erb HHH; Read ML; Gurney M; Archer LK; Ito S; Rumsby MG; Petrie JL; Clayton A; Maitland NJ; Collins AT Sci Rep; 2019 Mar; 9(1):5120. PubMed ID: 30914656 [TBL] [Abstract][Full Text] [Related]
4. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599 [TBL] [Abstract][Full Text] [Related]
5. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783 [TBL] [Abstract][Full Text] [Related]
6. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1. Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815 [TBL] [Abstract][Full Text] [Related]
7. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877 [TBL] [Abstract][Full Text] [Related]
8. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917 [TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel. Desarnaud F; Geck P; Parkin C; Carpinito G; Makarovskiy AN Cancer Biol Ther; 2011 Jan; 11(2):204-12. PubMed ID: 21057205 [TBL] [Abstract][Full Text] [Related]
10. Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential. Li Y; Basang Z; Ding H; Lu Z; Ning T; Wei H; Cai H; Ke Y BMC Cancer; 2011 Apr; 11():121. PubMed ID: 21466706 [TBL] [Abstract][Full Text] [Related]
11. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Shi GH; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Xiao WJ; Ma CG Acta Pharmacol Sin; 2010 Jul; 31(7):867-73. PubMed ID: 20581857 [TBL] [Abstract][Full Text] [Related]
12. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer. Lin F; Wen D; Wang X; Mahato RI Biomaterials; 2019 Feb; 192():95-108. PubMed ID: 30447399 [TBL] [Abstract][Full Text] [Related]
13. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437 [TBL] [Abstract][Full Text] [Related]
14. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Wu K; Xie D; Zou Y; Zhang T; Pong RC; Xiao G; Fazli L; Gleave M; He D; Boothman DA; Hsieh JT Clin Cancer Res; 2013 Sep; 19(17):4740-9. PubMed ID: 23838317 [TBL] [Abstract][Full Text] [Related]
15. Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms. Wang Z; Ravula R; Shi L; Song Y; Yeung S; Liu M; Lau B; Hao J; Wang J; Lam CW; Chow MS; Huang Y Oncotarget; 2016 Sep; 7(38):61246-61261. PubMed ID: 27487134 [TBL] [Abstract][Full Text] [Related]
16. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73. Gao Q; Zheng J Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904 [TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Li Y; Hong X; Hussain M; Sarkar SH; Li R; Sarkar FH Mol Cancer Ther; 2005 Mar; 4(3):389-98. PubMed ID: 15767548 [TBL] [Abstract][Full Text] [Related]
18. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132 [TBL] [Abstract][Full Text] [Related]
19. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298 [TBL] [Abstract][Full Text] [Related]
20. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Al Nakouzi N; Cotteret S; Commo F; Gaudin C; Rajpar S; Dessen P; Vielh P; Fizazi K; Chauchereau A Oncotarget; 2014 Feb; 5(3):667-78. PubMed ID: 24525428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]